A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
Fiche publication
Date publication
septembre 2021
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
Tous les auteurs :
Oza AM, Dubois F, Hegg R, Hernández CA, Finocchiaro G, Ghiringhelli F, Zamagni C, Nick S, Irahara N, Perretti T, Colombo N
Lien Pubmed
Résumé
Bevacizumab has been studied in numerous clinical trials in multiple types of cancer; however, patients may receive bevacizumab over an extended period of time. This study assessed the long-term safety and tolerability of bevacizumab among patients with solid tumors.
Mots clés
Bevacizumab, cancer, long-term treatment, safety, solid tumor
Référence
Oncologist. 2021 Sep 9;: